Granted Patent B2

US 12,662,492 · App. 16/980,503 · Granted Jun 23, 2026

Inventors: Sang Jeon Chung (Seoul, KR); Ju Hwan Kim (Gyeonggi-do, KR); Young Geun Lee (Gyeonggi-do, KR); Tae Jin Lee (Gyeonggi-do, KR); Jin Woo Seo (Gyeonggi-do, KR)

Assignee: ABTIS CO., LTD.

C07D498/18A61K47/68031A61K47/68033A61K47/68037A61K47/6855A61K47/6889A61P35/00C07D207/46C07K16/32

Abstract

Claims (26)

1 . A peptide-compound conjugate having a structure of formula 6-3:

D-C-A-W-H-(Xa 1 )′-G-E-L-V—W-C-T (SEQ ID NO: 16),  [formula 6-3]

wherein,

D is an aspartic acid residue, C is a cysteine residue, A is an alanine residue, W is a tryptophan residue, H is a histidine residue, G is a glycine residue, E is a glutamic acid residue, L is a leucine residue, V is a valine residue, and T is a threonine residue, and

(Xa 1 )′ is

wherein

H 1 is a click chemistry functional group selected from the group consisting of a terminal alkyne, an azide, a strained alkyne, a diene, a dienophile, a dibenzocyclooctyne-amine, a trans-cyclooctene, a norbornene, an alkene, a thiol, and a tetrazine,

D 1 is selected from a covalent bond, C 1-4 alkylene or heteroalkylene, C 2-4 alkenylene, C 2-4 alkynylene, and C 3-8 cycloalkylene,

X 1 is S,

D 2 is selected from C 1-7 alkylene, C 2-7 alkenylene, C 2-7 alkynylene, and C 3-8 cycloalkylene,

D 3 is a covalent bond, or C 1-3 alkylene, and

X 3 is NH,

wherein the peptide exhibits the activity of binding to human immunoglobulin G (IgG), and

wherein the cysteine residue adjacent to the N-terminus of formula 6-3 and the cysteine residue adjacent to the C-terminus of formula 6-3 are optionally linked.

2 . The peptide-compound conjugate according to claim 1 ,

wherein D 1 is a covalent bond and D 2 is methylene.

3 . The peptide-compound conjugate according to claim 1 , wherein D 1 is selected from a covalent bond and —(CH 2 ) 1-4 —.

4 . The peptide-compound conjugate according to claim 1 , wherein D 1 comprises at least one heteroatom.

5 . The peptide-compound conjugate according to claim 1 , wherein D 2 is —CH 2 —.

6 . The peptide-compound conjugate according to claim 1 , wherein D 3 is selected from a covalent bond and —(CH 2 ) 1-3 —.

7 . The peptide-compound conjugate according to claim 1 , wherein D 1 is —CH 2 OCH 2 —.

8 . The peptide-compound conjugate according to claim 1 , wherein D 1 is —CH 2 CH 2 OCH 2 —.

9 . The peptide-compound conjugate according to claim 1 , wherein a moiety comprising polyethylene glycol (PEG) is linked to a N-terminal amine group of the aspartic acid residue.

10 . The peptide-compound conjugate according to claim 1 , wherein a moiety represented by the following structure is linked to a N-terminal amine group of the aspartic acid residue:

11 . The peptide-compound conjugate of claim 1 , wherein the peptide-compound conjugate is represented by any one selected from the following structures:

12 . The peptide-compound conjugate of claim 1 , wherein the peptide-compound conjugate is represented by the following structure:

Assignments (2)

Continuity (2)

References Cited (37)